Financial

Integra Lifesciences Holdings Corp (IART) Earns “Buy” Rating from Oppenheimer

By Maddie Sorenson

Integra Lifesciences Holdings Corp (NASDAQ:IART)‘s stock had its “buy” rating reaffirmed by investment analysts at Oppenheimer in a research note issued on Wednesday, Analyst Ratings Net reports.

Shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) traded down 0.23% during mid-day trading on Wednesday, reaching $68.44. 49,298 shares of the company’s stock traded hands. The stock’s market cap is $2.53 billion. The firm has a 50 day moving average price of $64.48 and a 200-day moving average price of $62.40. Integra Lifesciences Holdings Corp has a 12 month low of $47.82 and a 12 month high of $68.84.

Integra Lifesciences Holdings Corp (NASDAQ:IART) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.01. The business earned $226.40 million during the quarter, compared to analyst estimates of $224.08 million. During the same quarter last year, the firm earned $0.71 EPS. Integra Lifesciences Holdings Corp’s revenue for the quarter was up 14.6% compared to the same quarter last year. On average, analysts predict that Integra Lifesciences Holdings Corp will post $3.09 earnings per share for the current fiscal year.

READ MORE HERE

Print Friendly, PDF & Email
Tags

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close